Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
24 2월 2025 - 9:01PM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company utilizing its novel proprietary ARCUS®
platform to develop in vivo gene editing therapies, including gene
elimination, gene insertion, and gene excision programs, today
announced that the company will present preclinical data from the
PBGENE-DMD program for the treatment of Duchenne muscular dystrophy
(DMD) during an oral presentation at the 2025 Muscular Dystrophy
Association (MDA) Clinical & Scientific Conference being held
March 16-19, 2025.
Presentation Details:
Title: ARCUS-Mediated Excision of Exons 45-55 Leads to
Functional Del45-55 Dystrophin and Restoration of Skeletal
Muscle-Function for the Treatment of DMD Date and Time:
Wednesday, March 19, 2025, 8:00 AM CT
The abstract is now publicly accessible through the MDA website
here.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform that differs from other
technologies in the way it cuts, its smaller size, and its simpler
structure. Key capabilities and differentiating characteristics may
enable ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene
editing therapies for sophisticated gene edits, including gene
insertion (inserting DNA into gene to cause expression/add
function), elimination (removing a genome e.g. viral DNA or mutant
mitochondrial DNA), and excision (removing a large portion of a
defective gene by delivering two ARCUS nucleases in a single AAV
such as in the DMD program for oral presentation at the MDA
Clinical & Scientific Conference).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250224445387/en/
Investor and Media Contact: Naresh Tanna Vice President
of Investor Relations naresh.tanna@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Precision BioSciences (NASDAQ:DTIL)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
